Duration of Antiplatelet Therapy After Complex Percutaneous Coronary Intervention In Patients at High Bleeding Risk: a MASTER DAPT trial sub-analysis

Marco Valgimigli, M.D., Ph.D., Pieter C. Smits, M.D., Ph.D., Enrico Frigoli, M.D., Dario Bongiovanni, M.D., Jan Tijssen, Ph.D., Thomas Hovasse, M.D., Al. Mafragi, M.D., W.T. Ruifrok, M.D., Dimitar Karageorgiev, M.D., Adel Aminian, M.D, Stefano Garducci, M.D., Bela Merkely, M.D., Helen Routledge, M.D., Kenji Ando, M.D., Josè Francisco Diaz Fernandez, M.D., Thomas Cuisset, M.D., Fazila Tun Nesa Malik, M.D., Majdi Halabi, M.D., Loic Belle, M.D., Jehangir Din, M.D., Farzin Beygui, M.D., Atul Abhyankar, M.D., Krzysztof Reczuch, M.D., Giovanni Pedrazzini, M.D., Dik Heg, Ph.D., Pascal Vranckx, M.D., Ph.D., for the MASTER DAPT Investigators*

From the Cardiocentro Institute, Ente Ospedaliero Cantonale, Università della Svizzera Italiana (USI), CH- 6900 Lugano, Switzerland (M.V., D.B., G.P); CTU Bern, University of Bern, Bern, Switzerland (E.F., D.H.); Amsterdam University Medical Center, the Netherlands (J.T.); Ramsay Générale de Santé, ICPS, Hôpital Jacques Cartier, Massy, France (T.H.); Department of Cardiology, Zorgsaam Hospital, Terneuzen, the Netherlands (A.M.); Treant Zorggroep, Emmen, the Netherlands, (W.T. R.); BAL Sveta Karidad, Plovdiv, Bulgaria (D.K.); Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium (A.A.); Unita' Operativa Complessa di Cardiologia, ASST Di Vimercate (MB), Vimercate, Italy (S.G.); Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.); Worcestershire Royal Hospital, Worcester, UK (H.R.); Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan (K.A.); Department of Cardiology, Hospital Universitario Juan Ramón Jiménez, Huelva, Spain (J.F.D.F.); Assistance Publique - Hôpitaux de Marseille, Centre Hospitalier Universitaire La Timone, Service de Cardiologie, Marseille, France (T.C.); National Heart Foundation Hospital and Research Institute, Dhaka, Bangladesh (F.T.N.M.); Department of Cardiology, Ziv Medical Center, Safed, Israel (M.H.); Cardiology Department, Hospital of Annecy, Annecy, France (L.B.); Royal Bournemouth Hospital, East Bournemouth, UK (J.D.); Service

de Cardiologie, Centre Hospitalier Universitaire (CHU) de Caen Normandie, Caen, France; Électrophysiologie et imagerie des lésions d'ischémie-reperfusion myocardique, Normandie Univ, UNICAEN, Caen, France (F.B.); Department of Cardiology, Shree B. D. Mehta Mahavir Heart Institute, Surat, India (A.A.); Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland (K.R.); Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands (P.C.S.); Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis Hasselt, faculty of medicine and life sciences University of Hasselt, Hasselt, Belgium (P.V.).

*A complete list of the MASTER DAPT investigators is provided in the Supplementary Appendix.

The MASTER DAPT trial is conducted with support from Terumo.

Corresponding author. Marco Valgimigli, Cardiocentro Institute, Ente Ospedaliero Cantonale, Università della Svizzera Italiana (USI), CH- 6900 Lugano, Switzerland.

marco.valgimigli@cardiocentro.org

Phone: +41 91 805 33 47

Fax: +41 91 805 3034

Abstract:

Aims: To assess the effects of 1- or ≥3-month dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents for complex percutaneous coronary intervention (PCI) and/or acute coronary syndrome (ACS).

Methods and results: In the MASTER DAPT trial, 3383 patients underwent noncomplex (abbreviated DAPT, n=1707; standard DAPT, n=1676) and 1196 complex (abbreviated DAPT, n=588; standard DAPT, n=608) PCI. Co-primary outcomes at 335 days were net adverse clinical events (NACE; composite of all-cause death, myocardial infarction, stroke, and Bleeding Academic Research Consortium [BARC] 3 or 5 bleeding events); major adverse cardiac or cerebral events (MACCE; all-cause death, myocardial infarction, and stroke); and type 2, 3, or 5 BARC bleeding.

NACE and MACCE did not differ with abbreviated versus standard DAPT among patients with complex (hazard ratio [HR]: 1.03, 95% confidence interval [CI]: 0.69–1.52, and HR: 1.24, 95% CI: 0.79–1.92, respectively) and noncomplex PCI (HR: 0.90, 95% CI: 0.71–1.15, and HR: 0.91, 95% CI: 0.69–1.21; $P_{interaction}$=0.60 and 0.26, respectively). BARC 2, 3 or 5 was reduced with abbreviated DAPT in patients with and without complex PCI (HR: 0.64; 95% CI: 0.42-0.98, and HR: 0.70; 95% CI: 0.55-0.89; $P_{interaction}$=0.72). Among the 2,816 patients with complex PCI and/or ACS, NACE and MACCE did not differ and BARC 2, 3 or 5 was lower with abbreviated DAPT.

Conclusion:

In HBR patients free from recurrent ischemic events at 1 month, DAPT discontinuation was associated with similar NACE and MACCE and lower bleeding rates compared with standard DAPT, regardless of PCI or patient complexity.

Keywords:

Percutaneous coronary intervention, high bleeding risk, dual antiplatelet therapy, complex intervention.

This trial is registered with ClinicalTrials.gov, number NCT03023020, and is closed to new participants, with follow-up completed.

Key Question

To assess the consistency of the treatment effects of 1- or ≥ 3-month dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients with complex percutaneous coronary intervention (PCI) and/or acute coronary syndrome (ACS).

Key Finding

One-month DAPT after PCI with biodegradable-polymer sirolimus-eluting stent in HBR patients was associated with similar net adverse clinical events (NACE) and major adverse cardiac or cerebral events (MACCE) and lower bleeding rates compared with standard DAPT, regardless of PCI complexity and/or ACS.

Take Home Message

In HBR patients undergoing PCI without recurrent ischemic events in the first 30 days after coronary intervention, PCI complexity and/or ACS does not justify a DAPT regimen longer than one month.



Graphical Abstract

INTRODUCTION

Patients undergoing percutaneous coronary intervention (PCI) with severe coronary artery disease (CAD) and challenging lesion subsets require complex procedures and remain at increased risk of short- and long-term adverse ischemic events[1-5].

A prior retrospective analysis of 6 randomized controlled trials, including 9,577 patients, showed that among 1,680 unselected complex PCI patients, the risk of major adverse cardiac events was lower with a 12-month compared with a 3–6-month dual antiplatelet therapy (DAPT) regimen, with significant treatment duration by PCI complexity interaction testing[2]. A subsequent analysis which gathered individual patient data from 8 randomized controlled trials and 14,963 patients, suggested that the bleeding risk might be an additional treatment modifier, based on the observation that an ischemic benefit with prolonged treatment was observed only in patients not at high bleeding risk (HBR) who underwent complex PCI and/or were intervened upon with acute coronary syndrome (ACS) (complex patient group)[1]. No benefit in terms of ischemic endpoints was noted with prolonged DAPT in HBR patients, irrespective of PCI or patient complexity[1]. On the other hand, and regardless of PCI or patient complexity, extended DAPT duration remains associated with an increased risk of major bleeding[1, 2], especially among HBR patients[1].

The aforementioned evidence informed the design of the MASTER DAPT (The Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen) trial, which randomised HBR patients to one- or at least 3-month DAPT, irrespective of PCI complexity and/or ACS at presentation[6]. The primary results showed that one month of DAPT was noninferior to treatment continuation for at least 2 additional months for the occurrence of net and major adverse clinical events and reduced major or clinically relevant nonmajor bleeding in the overall HBR population[7]. In this study, we conducted a prespecified analysis to assess the consistency of the treatment effects of one-month versus a more prolonged DAPT duration based on PCI and patient (i.e. complex PCI and/or ACS) complexity.

METHODS

Study design

The design and the primary endpoint results of the MASTER DAPT (ClinicalTrials.gov number, NCT03023020) investigator-initiated, randomized, open-label, noninferiority trial with sequential superiority testing in largely unselected patients at HBR following implantation of a biodegradable polymer-coated Ultimaster™ (Terumo Corporation, Tokyo, Japan) sirolimus-eluting stent, were reported previously[6, 7]. Ethics approval was obtained in each country and centre. All patients gave written informed consent. An independent data safety monitoring board regularly reviewed the conduct of the trial and the safety of the patients.

Study patients

Patients at high risk for bleeding who underwent treatment of all planned coronary artery stenoses with Ultimaster stent implantation for acute or chronic coronary syndromes were eligible if they remained uneventful until the time of randomization. Patients were considered at HBR if at least one of the following criteria applied: oral anticoagulant (OAC) therapy for at least 12 months, recent (<12 months) non-access site bleeding episode(s) that required medical attention, previous bleeding episode(s) that required hospitalization if the underlying cause had not been definitively treated, age ≥75 years, systemic conditions associated with an increased bleeding risk (e.g. haematological disorders or any known coagulation disorder associated with increased bleeding risk), documented anaemia (defined as repeated haemoglobin levels <11 g/dL or transfusion within 4 weeks before randomization), need for chronic treatment with steroids or non-steroidal anti-inflammatory drugs (NSAIDs), diagnosed malignancy (other than skin), stroke at any time or transient ischaemic attack in the previous 6 months, and PRECISE-DAPT score ≥25[6-8].

Exclusion criteria were minimal and limited to implantation of a non-study stent within the previous 6 months or a bioresorbable scaffold at any time before the index procedure, or if they underwent treatment because of an in-stent restenosis or stent thrombosis.

Complex PCI was primarily defined as a procedure with at least one of the following angiographic characteristics: 3 vessels treated, ≥3 stents implanted, ≥3 lesions treated, bifurcation with 2 stents

implanted, total stent length >60 mm, or chronic total occlusion as target lesion[1, 2]. An alternative and more comprehensive complex PCI definition which includes, in addition to all previous complex PCI criteria, also left main or graft intervention has also been used as sensitivity analysis[9]. Complex patients were defined as those fulfilling the primary complex PCI definition and/or with ACS, including ST-segment elevation or non-ST-segment elevation myocardial infarction or unstable angina.

Randomization and follow-up

Patients were centrally randomized (1:1 ratio) to an open-label abbreviated or non-abbreviated antiplatelet therapy regimen 30 to 44 days after the index procedure. Randomization was concealed using a web-based system; randomization sequences were computer generated, blocked, with randomly selected block sizes of 2, 4, or 6, and were stratified by site, history of acute myocardial infarction within the past 12 months, and clinical indication for at least 12 months of OAC therapy. Follow-up visits occurred at 60±14 and 150±14 days after randomization, preferably as on-site visits, and at 335±14 days after randomization, exclusively as an on-site visit. Three independent clinical research organisations (CERC, Massy, France; Cardialysis, Rotterdam, the Netherlands; and CVQuest, Tokyo, Japan) performed on-site and remote monitoring visits, verified the source documents, and collected source material for event adjudication. All events were adjudicated by an independent adjudication committee that was unaware of the treatment allocations. All data were stored at a central database (CTU, Bern, Switzerland).

RANDOMIZED TREATMENT

Patients randomly allocated to the abbreviated treatment group immediately discontinued DAPT and continued single antiplatelet therapy (SAPT) until study completion, except for those receiving OAC, who continued SAPT up to 6 months after the index procedure. Patients allocated to the standard treatment group continued DAPT for at least 5 additional months (6 months after the index procedure) or, for those receiving OAC, for at least 2 additional months (3 months after the index procedure) and continued thereafter on SAPT. Antiplatelet and anticoagulant treatments were dosed according to authorizations for use and locally approved regimens; detailed descriptions of the two treatment regimens are provided in the Supplementary Appendix.

Outcomes

The three ranked primary outcomes were net adverse clinical events (NACE) (a composite of death from any cause, myocardial infarction, stroke, or major bleeding), major adverse cardiac or cerebral events (MACCE) (a composite of death from any cause, myocardial infarction, or stroke), and major or clinically relevant non-major bleeding (composite of type 2, 3, or 5 Bleeding Academic Research Consortium [BARC] bleeding); cumulative incidences were assessed at 335 days.

The secondary outcomes included the individual components of the three co-primary outcomes; the composite of cardiovascular death, myocardial infarction, and stroke; the composite of cardiovascular death, myocardial infarction, definite or probable stent thrombosis, the composite of stroke and transient ischaemic attack; and all bleeding events, adjudicated according to the BARC classifications.

All outcomes were prespecified[6, 7]. All analyses evaluated the occurrence of the adjudicated outcomes between randomization and 335 days.

Statistical analysis

The data were analysed according to the intention-to-treat principle. Outcomes were assessed separately for patients with or without complex PCI procedure, by calculating hazard ratios (HR) with 95% confidence intervals (CI).

For patients with a primary outcome, time-to-event was calculated as the difference between the date of occurrence of the outcome event and the date of randomization plus 1. For patients with incomplete clinical follow-up, time to censoring was defined as the difference between the dates of last known clinical status and randomization plus 1. Kaplan-Meier calculations included all (first) adjudicated outcome events that occurred between randomization and 335 days thereafter according to the randomized treatment assignment, irrespective of the DAPT regimen received at the time of the outcome event. HR and 95% CI were generated for primary and secondary outcomes with the use of Cox proportional hazards regression analysis with censoring at end of study and at the time of death. Competing risk of death (subdistribution HR with 95% CI) and the Aalen-Johansen cumulative incidences (with 95% CI) were computed for BARC bleeding endpoints following the Fine and Gray methodology[10]. Absolute risk differences are shown as percentage points. Numbers needed to treat for harm (NNTH) or benefit (NNTB) were calculated dividing 1 by absolute risk difference for various endpoints between randomized groups.

P-values for testing homogeneity of the HR in subgroups of patients were derived in Cox proportional hazards models with the interaction term for treatment group (abbreviated vs standard) and complex PCI (yes vs no) tested using one degree of freedom. The 95% CI and *P*-values for interaction were not adjusted for multiplicity and should not be used to infer definitive treatment effects. Details on the statistical analysis have been published[6, 7, 11].

RESULTS

From February 28, 2017 through December 5, 2019, 5204 patients (at 140 sites in 30 countries) were consented, of whom 1359 (26.1%) patients with and 3845 (73.9%) without complex PCI; a total of 1196 (88%) patients with complex and 3383 (88%) without complex PCI were randomized (median 34 days post stenting, interquartile range: 32 to 39) to an abbreviated (n=2295 patients; complex PCI, n=588; noncomplex PCI, n=1707) or a standard (n=2284 patients complex PCI, n=608; noncomplex PCI, n=1676) DAPT regimen. Clinical and procedural characteristics of the patients who did not undergo randomization are shown in the supplementary appendix and were consistent across complex PCI strata (**Tables S1-2**). More patients in the non-complex PCI group withdrew after consent due to medical reasons whereas more patients in the complex PCI group died before randomization (**Table S3**). Complex PCI criteria distribution is shown in **Table S4**.

Patients with complex PCI were more likely to be older, have a history of prior myocardial infarction, arterial thromboembolism, chronic renal failure or non-ST-segment elevation acute coronary syndrome, but less likely to have prior bleeding or unstable angina, compared with the noncomplex PCI group (**Tables S5, S6**). Procedural characteristics were largely imbalanced between complex and noncomplex PCI patients (**Tables S6).** Antiplatelet therapies in complex and noncomplex PCI patients as stratified by study group are shown in **Figure 1** and **Table S7**. Type of antiplatelet therapy before and after randomization in patients with or without complex PCI in the abbreviated arm is shown in **Table S8**. Complex PCI patients incurred more myocardial infarctions compared with noncomplex PCI patients (3.6% vs. 2.0%; HR: 1.78, 95% CI:1.21–2.61, P=0.004), which was only marginally explained by a numerical difference in definite or probable stent thrombosis between groups (0.9% vs. 0.4%; HR: 2.17, 95% CI:0.95–4.94, P=0.066, **Table S9**).

Baseline, angiographic and procedural characteristics, stratified by PCI complexity, were well balanced between the two antiplatelet regimens (**Tables 1 and S10)**.

Primary outcomes

NACE and MACCE did not differ with abbreviated versus standard DAPT regimens among patients with complex (HR: 1.03, 95% CI: 0.69–1.52, P=0.90, risk difference 0.27 [-2.85 to 3.39] and HR: 1.24, 95% CI: 0.79–1.92, P=0.349, risk difference 1.39 [-1.43 to 4.22], respectively) and non-complex PCI (HR: 0.90, 95% CI: 0.71–1.15, P=0.418, risk difference -0.74 [-2.53 to 1.06], and HR: 0.91, 95% CI: 0.69–1.21, risk difference -0.53 [-2.11 to 1.06], P=0.520; $P_{interaction}$=0.60 and 0.26, respectively). BARC 2, 3 or 5 bleeding was significantly and consistently reduced in patients with and without complex PCI (HR: 0.64; 95% CI: 0.42-0.98, p=0.038, risk difference -3.11 [-6.13 to -0.10] and HR: 0 .70; 95% CI: 0.55-0.89, risk difference -2.72 [-4.57 to -0.87], p=0.004; $P_{interaction}$=0.72) (**Table 2 and Figures 1, 2**). The primary bleeding endpoint remained reduced with abbreviated DAPT in patients with or without complex PCI at competing risk of death analyses (**Table S11**). The results remained entirely consistent when an alternative and more comprehensive complex PCI definition was explored at post-hoc analysis (**Table S12**).

Secondary outcomes

There was no overall evidence of heterogeneity of the treatment effects in relation to PCI complexity and none of the secondary endpoints differed between abbreviated and standard DAPT regimens in complex or noncomplex PCI groups, with the only exceptions for BARC 1 and BARC 2 bleeding, which were lower (HR: 0.58; 95% CI: 0.40-0.83, p=0.003, HR: 0.67; 95% CI: 0.50-0.90, p=0.007, respectively) or trended lower (HR: 0.61; 95% CI: 0.34-1.07, p=0.08, HR: 0.63; 95% CI: 0.38-1.02, p=0.06, respectively) with abbreviated compared with standard DAPT in noncomplex and complex PCI groups, respectively (**Table 2 and Figure 1**). The results remained entirely consistent when an alternative and more comprehensive complex PCI definition as explored in post-hoc analysis (**Table S12**).

Complex PCI and/or acute coronary syndrome

NACE and MACCE did not differ with abbreviated versus standard DAPT regimens among patients with complex PCI and/or ACS (n=2,816; HR: 0.94, 95% CI: 0.73–1.21, P=0.62 and HR: 1.00, 95% CI: 0.76–1.33, P=0.97, respectively) and noncomplex PCI without ACS (n=1743; HR: 0.92, 95% CI: 0.64–1.32, P=0.66 and HR: 0.91, 95% CI: 0.69–1.21, P=0.520; $P_{interaction}$=0.94 and 0.83, respectively) (**Table 3**).

BARC 2, 3 or 5 bleeding was significantly and consistently reduced in patients with or without complex PCI and/or ACS (HR: 0.70; 95% CI: 0.53-0.93, p=0.013 and HR: 0.66; 95% CI: 0.48-0.91, p=0.012; $P_{interaction}$=0.78). The primary bleeding endpoint remained reduced with abbreviated DAPT in patients with or without complex PCI and/or ACS at competing risk analyses (**Table S13**). The results remained entirely consistent with abbreviated versus standard DAPT regimens among ACS patients who underwent complex PCI (n=571) and ACS patients who underwent noncomplex PCI (n=1640, **Table 4 and Figure 3**).

Risk/Benefit tradeoff of abbreviated DAPT regimen

The NNTH for myocardial infarction and definite or probable stent thrombosis, calculated from between-group non-significant differences, were consistently higher than the NNTB for BARC 2, 3 or 5 and BARC 3 or 5, calculated from between-group significant or non-significant differences, in all complex PCI, complex PCI and/or ACS and complex PCI ACS patients with abbreviated compared with standard treatment (**Figure 4**).

DISCUSSION

The main findings of the current analysis from the international, multicenter, randomized MASTER DAPT trial, in which we examined the efficacy and safety of a one month vs. standard DAPT regimen in HBR patients after PCI, in relation to procedural or patient complexities, can be summarized as follows: (i) complex PCI or complex PCI and/or ACS at presentation did not affect the comparative efficacy and safety of an abbreviated vs. a more prolonged DAPT regimen in HBR patients. This observation is supported by negative interaction testing for the three ranked primary or major secondary endpoints; (ii) an abbreviated DAPT regimen was not associated with significantly higher risk of composite or individual ischemic events compared with standard DAPT among HBR patients with complex PCI or complex PCI and/or ACS at presentation; and (iii) an abbreviated DAPT regimen resulted in significantly lower major or clinically relevant nonmajor bleeding complications compared with a non-abbreviated DAPT regimen, which was consistent across complex PCI and complex PCI and/or ACS strata (Graphical abstract).

MASTER DAPT, by design, enrolled HBR patients who underwent PCI of all intended de-novo lesions with biodegradable polymer-coated sirolimus-eluting stent(s), without restrictions based on number, type or location of the treated stenosis or clinical presentation[6]. This drove a large proportion of study patients fulfilling complex PCI criteria (N=1,196 or 26%) and/or presented with ACS (N=2,211 or 48.3%) or

presented both (N=571 or 12.5%) characteristics. To the best of our knowledge, the current analysis represents the largest study investigating 1- vs. ≥ 3-month DAPT after complex PCI in HBR patients.

The analysis of consented versus included patients showed no discernable bias from PCI to 1-month randomization in relation to the presence or absence of complex PCI criteria; an identical proportion of patients (88%) with or without complex PCI entered the trial after being consented. Notably, 30-day mortality was higher in patients with one or more complex PCI criteria compared with the noncomplex PCI group, whereas from randomization to 335 days, complex PCI patients incurred more myocardial infarctions than noncomplex PCI patients, largely due to non-stent related occurrences. In the complex PCI group, definite or definite or probable stent thrombosis explained only 19% and 24% of the overall myocardial infarction cases, respectively. The corresponding figures in the noncomplex PCI group were 15% and 19%, respectively. These findings indicate that, even in the context of complex PCI patients with or without ACS, undergoing a relatively short (6 months) or very short (1 month) DAPT regimen, the majority of myocardial infarctions derive from non-stented coronary segments[12]. Bleeding risk was not higher in complex compared with noncomplex PCI patients, which is also a consistent finding with previous studies[13-15]. Therefore, the consistency of the treatment effects of an abbreviated compared with a more prolonged DAPT regimen across the spectrum of PCI complexities remains critical to assess. More specifically, whether an abbreviated course of treatment mitigates bleeding without increasing ischemic risks in selected patients who underwent complex PCI.

NACE or MACCE did not differ with abbreviated compared with standard DAPT in patients with or without complex PCI criteria with no signal of treatment-by-subgroup interaction. BARC 2, 3 or 5 bleeding was significantly and consistently reduced in patients with and without complex PCI. These findings suggest that PCI complexity does not justify *per se* a more prolonged course of DAPT, in excess of one month, in HBR patients who did not encounter recurrent ischemic events in the first 30 days after intervention. Our findings remained entirely consistent when the intersection between complex PCI and ACS at presentation (complex patients) was further investigated, therefore replicating prospectively, with an even shorted DAPT regimen, the previously published retrospective observations arising from a combined dataset of 8 trials which investigated 3 to 6 months versus DAPT versus 12 months or more of treatment duration[1]. Based on these prior findings, the control group of the present trial set DAPT duration at a

minimum of 3 months, with a median duration of 193 days (interquartile range, 102 to 366)[6]. The results of this analysis support the use of a further shortened DAPT duration (median 34 days; interquartile range, 31 to 39) in HBR patients with or without complex PCI and irrespective of concomitant ACS. Our study was powered for assessing the non-inferiority of NACE and MACCE in the overall study population based on absolute risk differences expected to represent 30% of the corresponding event rates. No non-inferiority claim is obviously possible when interpreting subgroup-analyses, to which this study is by definition underpowered. Therefore, similar to all subgroup analyses, our study is hypothesis-generating with respect to the risks and benefits of an abbreviated compared with a standard DAPT regimen in patients who underwent complex PCI and/or with ACS. Our results are consistent with prior studies which assessed the consistency of the treatment effects of a shortened DAPT regimen of either 1[4] or 3[9] month(s), followed by ticagrelor monotherapy compared with 12-month DAPT in patients who were not selected based on HBR criteria and underwent complex PCI[16].

When the secondary endpoints were separately appraised, the results observed in the over trial population were consistently replicated in patients with or without complex PCI, suggesting no significant excess of myocardial infarction, stent thrombosis or stroke with an abbreviated DAPT regimen, nor a significant difference of major bleeding. As observed in the overall trial population, there were numerical imbalances of myocardial infarction in disfavor, and of major bleeding in favor, of the abbreviated DAPT group in both complex and noncomplex PCI patients. The rate of definite or probable stent thrombosis was numerical lower with abbreviated compared with standard DAPT in the complex PCI group, which therefore did not explain the insignificant small excess of myocardial infarction observed with abbreviated DAPT in this patient subgroup. In the complex PCI patients, ticagrelor, rather than aspirin monotherapy, was more frequently selected after DAPT discontinuation in the abbreviated arm compared with noncomplex PCI patients. Ticagrelor monotherapy was shown more effective for myocardial infarction and stent thrombosis prevention compared with aspirin monotherapy[17,18]. However, in both complex and noncomplex PCI patients, clopidogrel remained the most frequently used antiplatelet therapy after DAPT in the abbreviated arm.

In the noncomplex PCI group, there was a small excess of stent thrombosis with abbreviated compared with standard DAPT, which explained 27% and 10% of the overall myocardial infarction events in the

abbreviated and standard groups, respectively. Our study was clearly underpowered for relatively rarer endpoints such as myocardial infarction or major bleeding and even more for stent thrombosis. As a result, despite nonsignificant, these observations may indicate the existence of a small risk of coronary ischemic events and a small benefit in terms of major bleeding with abbreviated DAPT, in both patients with or without complex PCI. The appraisal of the tradeoff between possible risks and possible benefit is essential as they have been shown to exert similar prognostic implications for mortality[19].

The computation of NNTH for myocardial infarction or stent thrombosis and NNTB for major or major and clinically relevant minor bleeding showed that the former were lower than the latter in complex PCI, complex PCI and/or ACS as well as complex PCI and ACS. Therefore, even assuming the existence of a tradeoff between risks and benefits in HBR patients in relation to DAPT duration, our analysis support the hypothesis that 1-month DAPT remains the preferrable treatment option in HBR patients who underwent complex PCI and did not experience ischemic recurrences in the first 1 month after treatment.

The present results need to be interpreted in light of the several imitations.

The absence of a universally accepted definition for complex PCI is notable. We used the criteria proposed by Giustino et al. because this approach integrated, by consensus, features of procedural complexity which were associated with higher risks in prior studies[2], have been adopted since then by multiple investigators[1, 4, 13-15] and this definition was used to generate the hypothesis, tested in the MASTER DAPT trial, that presence of HBR is a treatment modifier for DAPT duration, irrespective of PCI or patient complexity. However, results remained entirely consistent when an alternative and more comprehensive complex PCI definition was implemented, suggesting robust findings. In the overall trial, as well as in the current sub-analysis, an abbreviated DAPT regimen was associated with lower BARC 2 but not BARC 3 or 5 bleeding events. Randomization was not stratified based on PCI complexity. However, we stratified based on history of acute myocardial infarction within the past 12 months, which almost exclusively comprised patients with ACS at presentation, as stenting within 6 months prior to randomization was an exclusion criterion. Our trial included HBR patients who underwent biodegradable-polymer sirolimus-eluting stent implantation; consequently, our results may not extend to non-HBR patients or who receive other stent types. Patients with in-stent restenosis or stent thrombosis were ineligible. The type of monotherapy after discontinuing dual antiplatelet therapy was at discretion of the

treating physicians and our results should be interpreted taking into account that ticagrelor was more and aspirin was less frequently preferred as monotherapy options in complex compared with noncomplex PCI groups in the abbreviated arm. The type of monotherapy after DAPT discontinuation in the abbreviated arm may have influenced the treatment effects and its role cannot be easily addressed in the current analysis due to the large number of factors that may have influenced the choice.

In conclusion, in HBR patients who underwent complex or noncomplex PCI with biodegradable-polymer sirolimus-eluting stent implantation and did not encounter early recurrent ischemic events, the discontinuation of DAPT a median of 34 days after PCI, compared with continuation of treatment for a median duration of 193 days, was consistently associated with similar rates of NACE and MACCE and a lower rate of major or clinically relevant nonmajor bleeding.

Disclosure

Marco Valgimigli received an institutional grant from Terumo and consulting fees from Astra Zeneca, Terumo, Alvimedica/CID, Abbott Vascular, Daiichi Sankyo, Bayer, CoreFLOW, DORSIA Pharmaceuticals LTD, Vifor, Bristol Myers Squib SA, Biotronik, Boston scientific, Medtronic, Vesalio, Novartis, Chiesi, PhaseBio, ECRI. Pieter C. Smits received institutional grants from Microport, SMT, Daichy Sankyo and Abbott Vascular; consulting fees from Cavis and Abbott Vascular; honoraria from Abiomed, Terumo and Abbott Vascular; participated on advisory board of Terumo, Abbott Vascular and SMI. Bela Merkely received grants from Medtronic and Boston Scientific; Speaker fee from Biotronik, Abbott, Astra Zeneca, Boehringer Ingelheim and Novartis. Thomas Cuisset received consulting fees from Medtronic, Abbott vascular, Terumo and Boston Scientific; honoraria from Medtronic, Abbott vascular, Terumo and Boston Scientific. Fazila Tun Nesa Malik received consulting fees from Terumo. Krzysztof Reczuch received honoraria from Boston Scientific, Terumo and Astra Zeneca. Pascal Vranckx received consulting fees from Daiichi Sankyo, Novartis, CSL Behring and Bayer AG; honoraria from Daiichi Sankyo and Servier; participated on advisory board for Daiichi Sankyo. All other authors declared no conflict of interest.

ROLE OF THE FUNDING SOURCE

The study was sponsored by the European Cardiovascular Research Institute (ECRI), a non-profit organisation, and received grant support from Terumo. The sponsor and funder had no role in the study design, data collection, data monitoring, analysis, interpretation, or writing of the report.

REFERENCES

1. Costa F, Van Klaveren D, Feres F, James S, Raber L, Pilgrim T*, et al.* Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. J Am Coll Cardiol 2019;**73**(7):741-754.
2. Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid A*, et al.* Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. J Am Coll Cardiol 2016;**68**(17):1851-1864.
3. Valgimigli M, Landi A. Ischaemic and bleeding risk in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: is it time to REACT? Eur Heart J Acute Cardiovasc Care 2021;**10**(10):1125-1128.
4. Serruys PW, Takahashi K, Chichareon P, Kogame N, Tomaniak M, Modolo R*, et al.* Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. Eur Heart J 2019;**40**(31):2595-2604.
5. Jeppsson A, Petricevic M, Kolh P, Valgimigli M. 2017 European Society of Cardiology (ESC) focused update on dual antiplatelet therapy in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2018;**53**(1):3-4.
6. Frigoli E, Smits P, Vranckx P, Ozaki Y, Tijssen J, Juni P*, et al.* Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. Am Heart J 2019;**209**:97-105.
7. Valgimigli M, Frigoli E, Heg D, Tijssen J, Juni P, Vranckx P*, et al.*; MASTER DAPT Investigators. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. N Engl J Med 2021;**385**(18):1643-1655.
8. Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F*, et al.*; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017;**389**(10073):1025-1034.
9. Dangas G, Baber U, Sharma S, Giustino G, Mehta S, Cohen DJ*, et al.* Ticagrelor With or Without Aspirin After Complex PCI. J Am Coll Cardiol 2020;**75**(19):2414-2424.
10. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc 1999;**94**(446):496-509.
11. Smits PC, Frigoli E, Tijssen J, Juni P, Vranckx P, Ozaki Y*, et al.*; MASTER DAPT Investigators Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant

Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. Circulation 2021;**144**(15):1196-1211.

12. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG*, et al.*; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;**371**(23):2155-66.

13. Roh JW, Hahn JY, Oh JH, Chun WJ, Park YH, Jang WJ*, et al.* P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial. Cardiol J 2021;**28**(6):855-863.

14. Coughlan JJ, Aytekin A, Ndrepepa G, Schupke S, Bernlochner I, Mayer K*, et al.* Twelve-month clinical outcomes in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: insights from the ISAR-REACT 5 trial. Eur Heart J Acute Cardiovasc Care 2021;**10**(10):1117-1124.

15. Yamamoto K, Watanabe H, Morimoto T, Domei T, Ohya M, Ogita M*, et al.* Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial. Circ Cardiovasc Interv 2021;**14**(5):e010384.

16. Valgimigli M, Gragnano F, Branca M, Franzone A, Baber U, Jang Y*, et al.* P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ 2021;**373**:n1332.

17. Valgimigli M, Mehran R, Franzone A, da Costa BR, Baber U, Piccolo R*, et al.* Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. JACC Cardiovasc Interv 2021;**14**(4):444-456.

18. Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys PW*, et al.*; GLASSY Investigators. Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. J Am Coll Cardiol 2019;**74**(18):2223-2234.

19. Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ*, et al.* Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 2017;**38**(11):804-810.

Legends

Figure 1. Antiplatelet regimens in complex (A) and noncomplex (B) PCI patients.

Dark blue denotes dual antiplatelet therapy, light blue denotes single antiplatelet therapy (see Table S7 for type therefore and Table S8 for cross-overs), red denotes no antiplatelet therapy, black denotes deceased patients, white denotes no information.

DAPT, dual antiplatelet therapy; OAC, oral anticoagulation.

Figure 2. Clinical endpoints stratified by complexity of percutaneous coronary intervention

CI, confidence interval; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary intervention; BARC, bleeding academic research consortium

Figure 3. Kaplan-Meier curve for major or clinically relevant nonmajor bleeding stratified by complexity of percutaneous coronary intervention

CI, confidence interval; DAPT, dual antiplatelet therapy; HR, hazard ratio.

Figure 4. Clinical endpoints in acute coronary syndrome patients stratified by complexity of percutaneous coronary intervention

CI, confidence interval; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary intervention; BARC, Bleeding Academic Research Consortium

Graphical Abstract.

One-month DAPT after PCI with biodegradable-polymer sirolimus-eluting stent in high bleeding risk patients was associated with similar NACE and MACCE and lower bleeding rates compared with standard DAPT, regardless of PCI complexity and/or ACS.

Table 1. Baseline characteristics

	Abbreviated DAPT		Standard DAPT		Complex	Noncomplex
	Complex PCI	Noncomplex PCI	Complex PCI	Noncomplex PCI	p-value	p-value
	N = 588	N = 1707	N = 608	N = 1676		
Age, years (mean ± SD)	n = 588, 76.51 ± 8.17	n = 1707, 75.98 ± 8.88	n = 608, 76.78 ± 8.30	n = 1676, 75.66 ± 8.92	0.570	0.298
Male sex (n [%])	n = 588, 419 (71.3%)	n = 1707, 1171 (68.6%)	n = 608, 428 (70.4%)	n = 1676, 1153 (68.8%)	0.751	0.911
Body mass index, kg/m² (mean ± SD)	n = 588, 27.56 ± 4.61	n = 1707, 27.15 ± 4.70	n = 608, 27.58 ± 4.62	n = 1676, 27.39 ± 4.79	0.943	0.136
Family history of coronary artery disease (n [%])	n = 588, 162 (27.6%)	n = 1707, 394 (23.1%)	n = 608, 148 (24.3%)	n = 1676, 405 (24.2%)	0.210	0.466
Known Arterial hypertension (n [%])	n = 588, 473 (80.4%)	n = 1707, 1293 (75.7%)	n = 608, 468 (77.0%)	n = 1676, 1319 (78.7%)	0.158	0.045
Uncontrolled hypertension (n [%])	n = 588, 23 (3.9%)	n = 1707, 96 (5.6%)	n = 608, 35 (5.8%)	n = 1676, 82 (4.9%)	0.141	0.356
Known Diabetes mellitus (n [%])	n = 588, 202 (34.4%)	n = 1707, 552 (32.3%)	n = 608, 203 (33.4%)	n = 1676, 581 (34.7%)	0.760	0.155
Known Hyperlipidemia (n [%])	n = 588, 420 (71.4%)	n = 1707, 1122 (65.7%)	n = 608, 403 (66.3%)	n = 1676, 1152 (68.7%)	0.061	0.067
Smoker (n [%])	n = 588	n = 1702	n = 607	n = 1669	0.071	0.130
no - never smoked	287 (48.8%)	899 (52.8%)	336 (55.4%)	902 (54.0%)	0.024	0.490
yes - previous smoker	254 (43.2%)	620 (36.4%)	232 (38.2%)	622 (37.3%)	0.088	0.617
yes - current smoker	47 (8.0%)	183 (10.8%)	39 (6.4%)	145 (8.7%)	0.315	0.048
Known Peripheral/Vascular disease* (n [%])	n = 588, 75 (12.8%)	n = 1707, 168 (9.8%)	n = 608, 62 (10.2%)	n = 1676, 180 (10.7%)	0.174	0.396
Known Carotid artery disease* (n [%])	n = 588, 32 (5.4%)	n = 1707, 88 (5.2%)	n = 608, 38 (6.3%)	n = 1676, 106 (6.3%)	0.623	0.160
History of heart failure (n [%])	n = 588, 116 (19.7%)	n = 1707, 313 (18.3%)	n = 608, 119 (19.6%)	n = 1676, 319 (19.0%)	1.000	0.628
Left ventricular ejection fraction, % (mean ± SD)	n = 559, 53.05 ± 11.29	n = 1610, 53.63 ± 11.49	n = 581, 52.27 ± 11.65	n = 1547, 53.22 ± 11.81	0.250	0.324
Prior myocardial infarction (n [%])	n = 588, 124 (21.1%)	n = 1707, 310 (18.2%)	n = 608, 145 (23.8%)	n = 1676, 285 (17.0%)	0.268	0.391
Prior PCI (n [%])	n = 588, 159 (27.0%)	n = 1707, 435 (25.5%)	n = 608, 153 (25.2%)	n = 1676, 441 (26.3%)	0.469	0.583
Prior cerebrovascular event reported (n [%])	n = 588, 79 (13.4%)	n = 1707, 189 (11.1%)	n = 608, 76 (12.5%)	n = 1676, 226 (13.5%)	0.667	0.036
Stroke (n [%])	n = 588, 58 (9.9%)	n = 1707, 135 (7.9%)	n = 608, 56 (9.2%)	n = 1676, 161 (9.6%)	0.768	0.088
TIA (n [%])	n = 588, 27 (4.6%)	n = 1707, 59 (3.5%)	n = 608, 18 (3.0%)	n = 1676, 66 (3.9%)	0.171	0.467

Undetermined Cerebrovascular event (n [%])	n = 588, 3 (0.5%)	n = 1707, 8 (0.5%)	n = 608, 5 (0.8%)	n = 1676, 13 (0.8%)	0.726	0.281
Known History of Arterial thromboembolism (n [%])	n = 588, 14 (2.4%)	n = 1707, 17 (1.0%)	n = 608, 10 (1.6%)	n = 1676, 14 (0.8%)	0.413	0.719
Known History of Venous thromboembolism (n [%])	n = 588, 41 (7.0%)	n = 1707, 83 (4.9%)	n = 608, 34 (5.6%)	n = 1676, 81 (4.8%)	0.342	1.000
Prior CABG (n [%])	n = 588, 46 (7.8%)	n = 1707, 124 (7.3%)	n = 608, 46 (7.6%)	n = 1676, 125 (7.5%)	0.914	0.844
Prior Prosthetic mechanical heart valve (n [%])	n = 588, 8 (1.4%)	n = 1707, 35 (2.1%)	n = 608, 11 (1.8%)	n = 1676, 47 (2.8%)	0.646	0.180
Known Aortic Valve Stenosis (n [%])	n = 518, 22 (4.2%)	n = 1551, 69 (4.4%)	n = 550, 31 (5.6%)	n = 1501, 73 (4.9%)	0.326	0.607
Prior bleeding before/after qualifying PCI (n [%])	n = 588, 39 (6.6%)	n = 1707, 145 (8.5%)	n = 608, 34 (5.6%)	n = 1676, 141 (8.4%)	0.471	0.951
Known Chronic pulmonary disease (n [%])	n = 588, 72 (12.2%)	n = 1707, 183 (10.7%)	n = 608, 72 (11.8%)	n = 1676, 211 (12.6%)	0.859	0.097
Known Chronic Renal Failure (n [%])	n = 588, 131 (22.3%)	n = 1707, 287 (16.8%)	n = 608, 122 (20.1%)	n = 1676, 336 (20.0%)	0.358	0.017
Known Liver disease (n [%])	n = 588, 8 (1.4%)	n = 1707, 21 (1.2%)	n = 608, 8 (1.3%)	n = 1676, 24 (1.4%)	1.000	0.654
Atrial fibrillation (n [%])	n = 588, 180 (30.6%)	n = 1707, 590 (34.6%)	n = 608, 181 (29.8%)	n = 1676, 539 (32.2%)	0.753	0.145
Known History of cancer (n [%])	n = 588, 98 (16.7%)	n = 1707, 250 (14.6%)	n = 608, 98 (16.1%)	n = 1676, 253 (15.1%)	0.815	0.735
Known Active cancer (n [%])	n = 588, 41 (7.0%)	n = 1707, 69 (4.0%)	n = 608, 33 (5.4%)	n = 1676, 93 (5.5%)	0.282	0.044
Known Haematological or Coagulation Disorders (n [%])	n = 588, 86 (14.6%)	n = 1707, 204 (12.0%)	n = 608, 79 (13.0%)	n = 1676, 209 (12.5%)	0.451	0.674
Chronic treatment with steroids or NSAIDs (n [%])	n = 588, 60 (10.2%)	n = 1707, 142 (8.3%)	n = 608, 68 (11.2%)	n = 1676, 171 (10.2%)	0.640	0.066
Prior VKA (n [%])	n = 588, 67 (11.4%)	n = 1707, 260 (15.2%)	n = 608, 64 (10.5%)	n = 1676, 235 (14.0%)	0.644	0.331
Need for current treatment with OAC (n [%])	n = 588, 200 (34.0%)	n = 1707, 649 (38.0%)	n = 608, 215 (35.4%)	n = 1676, 605 (36.1%)	0.628	0.255
Clinical indication for 12 months OAC (n [%])	n = 588, 200 (34.0%)	n = 1707, 648 (38.0%)	n = 608, 214 (35.2%)	n = 1676, 604 (36.0%)	0.671	0.255
OAC treatment at randomization (n [%])	n = 200, 199 (99.5%)	n = 648, 643 (99.2%)	n = 214, 213 (99.5%)	n = 604, 601 (99.5%)	1.000	0.727
PRECISE-DAPT score¶ (mean ± SD)	n = 588, 27.13 ± 11.54	n = 1707, 26.70 ± 10.69	n = 608, 26.91 ± 10.59	n = 1676, 26.64 ± 11.22	0.732	0.865
Prior bleeding (n [%])	n = 588, 37 (6.3%)	n = 1707, 128 (7.5%)	n = 608, 29 (4.8%)	n = 1676, 126 (7.5%)	0.257	1.000
Hemoglobin, g/L (mean ± SD)	n = 588,13.08 ± 1.80	n = 1707, 13.29 ± 1.77	n = 608, 13.07 ± 1.81	n = 1676, 13.24 ± 1.79	0.951	0.439
White blood cell count¶, 109/L (mean ± SD)	n = 588, 8.73 ± 21.50	n = 1707, 8.13 ± 4.09	n = 607, 8.05 ± 4.07	n = 1676, 8.06 ± 3.12	0.440	0.542
Creatinine clearance MDRD, ml/min/1.73 m² (mean ± SD)	n = 588, 69.77 ± 24.20	n = 1707, 71.05 ± 23.91	n = 608, 69.68 ± 24.33	n = 1676, 71.48 ± 24.00	0.947	0.595

Reported are means with standard deviations (±SD), counts (% of patients).
TIA: transient ischemic attack; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; NSAID: non steroidal anti inflammatory drug; OAC: oral anticoagulation (vitamin K-antagonist VKA or NOAC).
¶calculated at screening visit. n=1 PRECISE Score calculated without risk due to white blood cell count.

Table 2. Clinical endpoints at 11 months post-randomization

	Complex PCI					Noncomplex PCI					
	Abbreviated DAPT	Standard DAPT	Hazard ratio (95% CI)	p-value	Absolute risk difference [95% CI]	Abbreviated DAPT	Standard DAPT	Hazard ratio (95% CI)	p-value	Absolute risk difference [95% CI]	interaction p-value
	N = 588	N = 608				N =1707	N =1676				
Net Adverse Clinical Events (NACE)	49 (8.35)	49 (8.08)	1.03 (0.69-1.52)	0.900	0.27 [-2.85 to 3.39]	123 (7.24)	133 (7.98)	0.90 (0.71-1.15)	0.418	-0.74 [-2.53 to 1.06]	0.595
Major Adverse Cardiac or Cerebral events (MACCE)	43 (7.33)	36 (5.94)	1.24 (0.79-1.92)	0.349	1.39 [-1.43 to 4.22]	95 (5.59)	102 (6.12)	0.91 (0.69-1.21)	0.520	-0.53 [-2.11 to 1.06]	0.256
Major or Clinically Relevant Nonmajor Bleeding (MCB)	35 (6.03)	55 (9.15)	0.64 (0.42-0.98)	0.038	-3.11 [-6.13 to -0.10]	113 (6.71)	156 (9.44)	0.70 (0.55-0.89)	0.004	-2.72 [-4.57 to -0.87]	0.723
Death	19 (3.24)	18 (2.97)	1.09 (0.57-2.07)	0.797	0.27 [-1.70 to 2.24]	56 (3.30)	63 (3.78)	0.87 (0.61-1.25)	0.449	-0.48 [-1.73 to 0.77]	0.553
Cardiovascular death	9 (1.55)	10 (1.66)	0.93 (0.38-2.28)	0.870	-0.11 [-1.54 to 1.32]	28 (1.66)	34 (2.06)	0.81 (0.49-1.33)	0.399	-0.40 [-1.31 to 0.52]	0.790
Non-cardiovascular death	6 (1.03)	7 (1.17)	0.88 (0.30-2.63)	0.825	-0.13 [-1.32 to 1.05]	23 (1.37)	21 (1.28)	1.07 (0.59-1.94)	0.818	0.09 [-0.68 to 0.87]	0.759
Undetermined death	4 (0.69)	1 (0.17)	4.12 (0.46-36.86)	0.205	0.52 [-0.23 to 1.28]	5 (0.30)	8 (0.49)	0.61 (0.20-1.87)	0.390	-0.19 [-0.61 to 0.24]	0.128
Cardiovascular or Undetermined death	13 (2.23)	11 (1.83)	1.22 (0.55-2.72)	0.631	0.41 [-1.20 to 2.01]	33 (1.95)	42 (2.53)	0.77 (0.49-1.21)	0.260	-0.58 [-1.59 to 0.42]	0.329
Cerebrovascular Accident	4 (0.70)	5 (0.84)	0.82 (0.22-3.07)	0.773	-0.14 [-1.14 to 0.86]	13 (0.78)	27 (1.64)	0.47 (0.24-0.91)	0.025	-0.87 [-1.61 to -0.12]	0.452
Stroke¶	3 (0.52)	4 (0.67)	0.77 (0.17-3.45)	0.736	-0.15 [-1.03 to 0.73]	9 (0.53)	19 (1.16)	0.46 (0.21-1.02)	0.057	-0.62 [-1.25 to 0.00]	0.552
ischemic Stroke	3 (0.52)	3 (0.50)	1.03 (0.21-5.10)	0.971	0.01 [-0.80 to 0.83]	8 (0.47)	15 (0.91)	0.52 (0.22-1.23)	0.138	-0.44 [-1.00 to 0.13]	0.461
hemorhagic Stroke	0 (0.00)	1 (0.17)	0.34 (0.01-8.33)	1.000	-0.17 [-0.49 to 0.16]	1 (0.06)	4 (0.25)	0.24 (0.03-2.19)	0.208	-0.18 [-0.45 to 0.08]	1.000
TIA	1 (0.18)	1 (0.17)	1.03 (0.06-16.45)	0.984	0.01 [-0.47 to 0.48]	4 (0.24)	8 (0.49)	0.49 (0.15-1.62)	0.242	-0.25 [-0.66 to 0.17]	0.628
Myocardial infarction	23 (3.97)	19 (3.17)	1.25 (0.68-2.30)	0.471	0.80 [-1.32 to 2.92]	37 (2.21)	30 (1.83)	1.21 (0.75-1.96)	0.436	0.38 [-0.58 to 1.34]	0.935
Definite or Probable Stent Thrombosis	4 (0.69)	6 (1.00)	0.69 (0.19-2.44)	0.562	-0.31 [-1.35 to 0.73]	10 (0.60)	3 (0.18)	3.27 (0.90-11.89)	0.072	0.41 [-0.01 to 0.84]	0.091
Definite Stent Thrombosis	4 (0.69)	4 (0.67)	1.03 (0.26-4.12)	0.965	0.02 [-0.92 to 0.96]	7 (0.42)	3 (0.18)	2.29 (0.59-8.85)	0.230	0.24 [-0.14 to 0.61]	0.419
Probable Stent Thrombosis	0 (0.00)	2 (0.33)	0.21 (0.01-4.36)	0.500	-0.33 [-0.79 to 0.13]	3 (0.18)	0 (0.00)	6.87 (0.36-132.90)	0.250	0.18 [-0.02 to 0.38]	1.000

Bleeding BARC classification											
Type 1	19 (3.28)	32 (5.34)	0.61 (0.34-1.07)	0.083	-2.06 [-4.37 to 0.25]	46 (2.73)	77 (4.65)	0.58 (0.40-0.83)	0.003	-1.93 [-3.21 to -0.65]	0.891
Type 2	26 (4.49)	42 (7.00)	0.63 (0.38-1.02)	0.061	-2.51 [-5.16 to 0.14]	76 (4.52)	110 (6.67)	0.67 (0.50-0.90)	0.007	-2.16 [-3.72 to -0.59]	0.824
Type 3	11 (1.90)	16 (2.67)	0.70 (0.33-1.52)	0.369	-0.77 [-2.47 to 0.93]	42 (2.50)	43 (2.61)	0.95 (0.62-1.46)	0.830	-0.10 [-1.17 to 0.97]	0.494
Type 3a	9 (1.55)	10 (1.67)	0.92 (0.38-2.27)	0.861	-0.12 [-1.55 to 1.32]	17 (1.01)	20 (1.21)	0.83 (0.44-1.59)	0.576	-0.20 [-0.91 to 0.52]	0.854
Type 3b	2 (0.35)	4 (0.67)	0.52 (0.09-2.82)	0.444	-0.32 [-1.13 to 0.49]	19 (1.13)	16 (0.97)	1.16 (0.60-2.26)	0.657	0.16 [-0.53 to 0.86]	0.381
Type 3c	1 (0.17)	2 (0.34)	0.52 (0.05-5.68)	0.588	-0.16 [-0.74 to 0.42]	6 (0.36)	7 (0.42)	0.84 (0.28-2.50)	0.754	-0.07 [-0.49 to 0.36]	0.717
Type 4	0 (0.00)	0 (0.00)				0 (0.00)	0 (0.00)				
Type 5	0 (0.00)	2 (0.34)	0.21 (0.01-4.36)	0.500	-0.34 [-0.80 to 0.13]	2 (0.12)	6 (0.37)	0.33 (0.07-1.62)	0.170	-0.25 [-0.58 to 0.09]	
Type 5a	0 (0.00)	0 (0.00)				0 (0.00)	2 (0.12)	0.20 (0.01-4.16)	0.245	-0.12 [-0.29 to 0.05]	1.000
Type 5b	0 (0.00)	2 (0.34)	0.21 (0.01-4.36)	0.500	-0.34 [-0.80 to 0.13]	2 (0.12)	4 (0.24)	0.49 (0.09-2.67)	0.409	-0.12 [-0.42 to 0.17]	
Type 3 or 5	11 (1.90)	18 (3.00)	0.63 (0.30-1.32)	0.219	-1.10 [-2.86 to 0.66]	44 (2.62)	49 (2.97)	0.88 (0.58-1.32)	0.529	-0.34 [-1.46 to 0.78]	0.435

Hazard ratio (95% CI) from Cox's time-to-first event analyses in ITT population. Continuity corrected risk ratios (95% CI) in case of zero events with Fisher's exact test p-value. Interaction p-value testing for modifying effect of Complex PCI (yes or no) on the hazard ratio scale. Absolute risk differences are shown as percentage points.
¶includes undetermined strokes.
NACE = Co-primary composite endpoint of all-cause death, myocardial infarction, stroke and bleeding BARC 3 or 5
MACCE = Co-primary composite endpoint of all-cause death, myocardial infarction, stroke
MCB = Co-primary composite endpoint of bleeding BARC 2, 3 or 5

1 **Table 3. Clinical endpoints at 11 months post-randomization with Complex PCI and/or Acute Coronary Syndrome**

	Complex PCI or ACS					Noncomplex PCI and no ACS					
	Abbreviated DAPT	**Standard DAPT**	**Hazard ratio (95% CI)**	**p-value**	**Absolute risk difference [95% CI]**	**Abbreviated DAPT**	**Standard DAPT**	**Hazard ratio (95% CI)**	**p-value**	**Absolute risk difference [95% CI]**	**interaction p-value**
	N =1433	N =1403				N = 862	N = 881				
Net Adverse Clinical Events (NACE)	117 (8.19)	121 (8.66)	0.94 (0.73-1.21)	0.622	-0.47 [-2.52 to 1.58]	55 (6.42)	61 (6.95)	0.92 (0.64-1.32)	0.655	-0.54 [-2.89 to 1.82]	0.935
Major Adverse Cardiac or Cerebral events (MACCE)	100 (7.00)	97 (6.95)	1.00 (0.76-1.33)	0.974	0.06 [-1.82 to 1.93]	38 (4.44)	41 (4.68)	0.95 (0.61-1.48)	0.816	-0.24 [-2.20 to 1.72]	0.833
Major or Clinically Relevant Nonmajor Bleeding (MCB)	86 (6.10)	117 (8.46)	0.70 (0.53-0.93)	0.013	-2.36 [-4.29 to -0.44]	62 (7.27)	94 (10.78)	0.66 (0.48-0.91)	0.012	-3.51 [-6.21 to -0.81]	0.781
Death	52 (3.64)	55 (3.94)	0.92 (0.63-1.35)	0.670	-0.30 [-1.71 to 1.11]	23 (2.69)	26 (2.97)	0.91 (0.52-1.59)	0.727	-0.28 [-1.84 to 1.28]	0.960
Cardiovascular death	24 (1.70)	27 (1.95)	0.87 (0.50-1.50)	0.609	-0.26 [-1.25 to 0.74]	13 (1.53)	17 (1.95)	0.78 (0.38-1.61)	0.505	-0.42 [-1.65 to 0.81]	0.827
Non-cardiovascular death	20 (1.42)	20 (1.45)	0.97 (0.52-1.81)	0.933	-0.03 [-0.92 to 0.85]	9 (1.06)	8 (0.92)	1.15 (0.44-2.98)	0.772	0.14 [-0.80 to 1.07]	0.772
Undetermined death	8 (0.57)	8 (0.58)	0.97 (0.37-2.59)	0.957	-0.02 [-0.58 to 0.55]	1 (0.12)	1 (0.11)	1.02 (0.06-16.38)	0.986	0.00 [-0.32 to 0.32]	0.974
Cardiovascular or Undetermined death	32 (2.25)	35 (2.52)	0.89 (0.55-1.44)	0.636	-0.27 [-1.40 to 0.86]	14 (1.64)	18 (2.06)	0.80 (0.40-1.60)	0.521	-0.42 [-1.69 to 0.85]	0.794
Cerebrovascular Accident	10 (0.72)	20 (1.46)	0.49 (0.23-1.04)	0.062	-0.74 [-1.52 to 0.03]	7 (0.82)	12 (1.38)	0.60 (0.23-1.51)	0.277	-0.56 [-1.54 to 0.43]	0.741
Stroke¶	8 (0.57)	13 (0.95)	0.60 (0.25-1.44)	0.254	-0.38 [-1.03 to 0.27]	4 (0.47)	10 (1.15)	0.41 (0.13-1.31)	0.131	-0.68 [-1.53 to 0.16]	0.607
ischemic stroke	7 (0.50)	10 (0.73)	0.68 (0.26-1.79)	0.436	-0.23 [-0.81 to 0.35]	4 (0.47)	8 (0.92)	0.51 (0.15-1.70)	0.274	-0.45 [-1.24 to 0.33]	0.714
hemorrhagic stroke	1 (0.07)	3 (0.22)	0.32 (0.03-3.12)	0.330	-0.15 [-0.43 to 0.14]	0 (0.00)	2 (0.23)	0.20 (0.01-4.16)	0.500	-0.23 [-0.55 to 0.09]	
TIA	2 (0.15)	7 (0.51)	0.28 (0.06-1.34)	0.110	-0.37 [-0.80 to 0.06]	3 (0.36)	2 (0.23)	1.53 (0.26-9.18)	0.639	0.13 [-0.38 to 0.64]	0.160
Myocardial infarction	47 (3.34)	41 (2.99)	1.12 (0.74-1.70)	0.601	0.36 [-0.94 to 1.66]	13 (1.53)	8 (0.92)	1.67 (0.69-4.02)	0.256	0.61 [-0.43 to 1.66]	0.422
Definite or Probable Stent Thrombosis	12 (0.85)	8 (0.58)	1.47 (0.60-3.58)	0.403	0.27 [-0.36 to 0.90]	2 (0.24)	1 (0.11)	2.04 (0.19-22.54)	0.559	0.12 [-0.27 to 0.52]	0.798
Definite Stent Thrombosis	9 (0.64)	6 (0.44)	1.46 (0.52-4.11)	0.469	0.20 [-0.34 to 0.75]	2 (0.24)	1 (0.11)	2.04 (0.19-22.54)	0.559	0.12 [-0.27 to 0.52]	0.802

Probable Stent Thrombosis	3 (0.21)	2 (0.15)	1.46 (0.24-8.76)	0.677	0.07 [-0.25 to 0.38]	0 (0.00)	0 (0.00)			
Bleeding BARC classification										
Type 1	40 (2.83)	72 (5.22)	0.53 (0.36-0.79)	0.002	-2.38 [-3.84 to -0.93]	25 (2.93)	37 (4.24)	0.69 (0.41-1.14)	0.146	-1.31 [-3.06 to 0.44]	0.447
Type 2	59 (4.19)	84 (6.10)	0.67 (0.48-0.94)	0.020	-1.91 [-3.55 to -0.26]	43 (5.05)	68 (7.81)	0.64 (0.44-0.93)	0.021	-2.76 [-5.07 to -0.45]	0.825
Type 3	30 (2.13)	34 (2.46)	0.86 (0.52-1.40)	0.535	-0.33 [-1.44 to 0.78]	23 (2.71)	25 (2.87)	0.94 (0.53-1.65)	0.824	-0.16 [-1.72 to 1.40]	0.811
Type 3a	16 (1.14)	23 (1.67)	0.68 (0.36-1.28)	0.228	-0.53 [-1.40 to 0.34]	10 (1.18)	7 (0.80)	1.46 (0.56-3.84)	0.440	0.38 [-0.56 to 1.32]	0.190
Type 3b	12 (0.85)	8 (0.58)	1.46 (0.60-3.58)	0.406	0.27 [-0.35 to 0.90]	9 (1.06)	12 (1.38)	0.77 (0.32-1.82)	0.544	-0.32 [-1.36 to 0.72]	0.308
Type 3c	3 (0.21)	3 (0.22)	0.98 (0.20-4.83)	0.975	0.00 [-0.35 to 0.34]	4 (0.47)	6 (0.69)	0.68 (0.19-2.42)	0.553	-0.22 [-0.94 to 0.50]	0.731
Type 4	0 (0.00)	0 (0.00)				0 (0.00)	0 (0.00)				
Type 5	2 (0.14)	5 (0.36)	0.39 (0.08-2.01)	0.260	-0.22 [-0.60 to 0.16]	0 (0.00)	3 (0.35)	0.15 (0.01-2.90)	0.250	-0.35 [-0.74 to 0.05]	
Type 5a	0 (0.00)	1 (0.07)	0.33 (0.01-8.09)	0.495	-0.07 [-0.21 to 0.07]	0 (0.00)	1 (0.12)	0.34 (0.01-8.33)	1.000	-0.12 [-0.35 to 0.11]	
Type 5b	2 (0.14)	4 (0.29)	0.49 (0.09-2.65)	0.405	-0.15 [-0.50 to 0.20]	0 (0.00)	2 (0.23)	0.20 (0.01-4.16)	0.500	-0.23 [-0.55 to 0.09]	
Type 3 or 5	32 (2.27)	39 (2.82)	0.80 (0.50-1.27)	0.339	-0.55 [-1.72 to 0.62]	23 (2.71)	28 (3.22)	0.84 (0.48-1.45)	0.527	-0.51 [-2.11 to 1.10]	0.890

Hazard ratio (95% CI) from Cox's time-to-first event analyses in ITT population. Continuity corrected risk ratios (95% CI) in case of zero events with Fisher's exact test p-value. Interaction p-value testing for modifying effect of Complex PCI or ACS vs none of these on the hazard ratio scale. Absolute risk differences are shown as percentage points.

¶includes undetermined strokes.

NACE = Co-primary composite endpoint of all-cause death, myocardial infarction, stroke and bleeding BARC 3 or 5

MACCE = Co-primary composite endpoint of all-cause death, myocardial infarction, stroke

MCB = Co-primary composite endpoint of bleeding BARC 2, 3 or 5

ACS = STEMI, NSTEMI and Unstable angina.

1 **Table 4. Clinical endpoints at 11 months post-randomization with Acute Coronary Syndrome**

	Complex PCI				Noncomplex PCI				
	Abbreviated DAPT	**Standard DAPT**	**Hazard ratio (95% CI)**	**p-value**	**Abbreviated DAPT**	**Standard DAPT**	**Hazard ratio (95% CI)**	**p-value**	**interaction p-value**
	N = 283	N = 288			N = 845	N = 795			
Net Adverse Clinical Events (NACE)	28 (9.89)	28 (9.77)	1.00 (0.59-1.69)	0.998	68 (8.08)	72 (9.11)	0.88 (0.63-1.23)	0.450	0.683
Major Adverse Cardiac or Cerebral events (MACCE)	25 (8.83)	23 (8.02)	1.09 (0.62-1.93)	0.757	57 (6.77)	61 (7.72)	0.87 (0.61-1.25)	0.457	0.508
Major or Clinically Relevant Nonmajor Bleeding (MCB)	18 (6.46)	30 (10.68)	0.58 (0.33-1.05)	0.071	51 (6.14)	62 (7.93)	0.76 (0.52-1.10)	0.146	0.464
Death	12 (4.24)	12 (4.18)	1.00 (0.45-2.23)	0.994	33 (3.92)	37 (4.68)	0.83 (0.52-1.33)	0.446	0.695
Cardiovascular death	6 (2.15)	8 (2.82)	0.75 (0.26-2.17)	0.598	15 (1.80)	17 (2.18)	0.83 (0.41-1.65)	0.587	0.888
Non-cardiovascular death	4 (1.43)	4 (1.41)	1.00 (0.25-4.01)	0.996	14 (1.69)	13 (1.67)	1.01 (0.47-2.14)	0.989	0.997
Undetermined death	2 (0.72)	0 (0.00)	5.09 (0.25-105.55)	0.245	4 (0.48)	7 (0.91)	0.53 (0.16-1.82)	0.317	
Cardiovascular or Undetermined death	8 (2.85)	8 (2.82)	1.00 (0.38-2.67)	0.996	19 (2.27)	24 (3.06)	0.74 (0.41-1.35)	0.327	0.603
Cerebrovascular Accident	1 (0.37)	3 (1.08)	0.33 (0.03-3.20)	0.341	6 (0.73)	15 (1.94)	0.37 (0.14-0.96)	0.040	0.931
Stroke¶	0 (0.00)	2 (0.72)	0.20 (0.01-4.15)	0.499	5 (0.61)	9 (1.16)	0.52 (0.17-1.55)	0.239	
ischemic Stroke	0 (0.00)	1 (0.36)	0.34 (0.01-8.31)	1.000	4 (0.48)	7 (0.90)	0.53 (0.16-1.82)	0.316	
hemorhagic Stroke	0 (0.00)	1 (0.36)	0.34 (0.01-8.31)	1.000	1 (0.12)	2 (0.26)	0.47 (0.04-5.14)	0.533	1.000
TIA	1 (0.37)	1 (0.36)	1.00 (0.06-15.93)	0.998	1 (0.12)	6 (0.78)	0.16 (0.02-1.29)	0.084	0.295
Myocardial infarction	15 (5.39)	12 (4.27)	1.26 (0.59-2.69)	0.552	24 (2.90)	22 (2.85)	1.02 (0.57-1.82)	0.946	0.667
Definite or Probable Stent Thrombosis	3 (1.08)	5 (1.79)	0.60 (0.14-2.51)	0.485	8 (0.97)	2 (0.26)	3.75 (0.80-17.67)	0.094	0.089
Definite Stent Thrombosis	3 (1.08)	3 (1.08)	1.00 (0.20-4.95)	0.999	5 (0.61)	2 (0.26)	2.34 (0.45-12.08)	0.309	0.467
Probable Stent Thrombosis	0 (0.00)	2 (0.71)	0.20 (0.01-4.15)	0.499	3 (0.36)	0 (0.00)	6.59 (0.34-127.38)	0.250	1.000
Bleeding BARC classification									

Type 1	9 (3.25)	16 (5.68)	0.56 (0.25-1.26)	0.159	21 (2.52)	40 (5.12)	0.49 (0.29-0.82)	0.007	0.773
Type 2	13 (4.69)	22 (7.88)	0.58 (0.29-1.15)	0.117	33 (3.98)	42 (5.40)	0.73 (0.46-1.15)	0.170	0.594
Type 3	6 (2.15)	8 (2.85)	0.75 (0.26-2.16)	0.592	19 (2.29)	18 (2.30)	0.99 (0.52-1.88)	0.964	0.665
Type 3a	5 (1.79)	5 (1.79)	1.00 (0.29-3.46)	0.999	7 (0.84)	13 (1.67)	0.50 (0.20-1.26)	0.142	0.379
Type 3b	1 (0.36)	2 (0.70)	0.50 (0.05-5.56)	0.576	10 (1.21)	4 (0.51)	2.34 (0.73-7.46)	0.151	0.257
Type 3c	0 (0.00)	1 (0.37)	0.34 (0.01-8.31)	1.000	2 (0.24)	1 (0.13)	1.87 (0.17-20.67)	0.608	
Type 4	0 (0.00)	0 (0.00)			0 (0.00)	0 (0.00)			
Type 5	0 (0.00)	2 (0.72)	0.20 (0.01-4.15)	0.499	2 (0.25)	3 (0.39)	0.62 (0.10-3.73)	0.604	1.000
Type 5a	0 (0.00)	0 (0.00)			0 (0.00)	1 (0.13)	0.31 (0.01-7.60)	0.485	1.000
Type 5b	0 (0.00)	2 (0.72)	0.20 (0.01-4.15)	0.499	2 (0.25)	2 (0.26)	0.93 (0.13-6.61)	0.944	
Type 3 or 5	6 (2.15)	10 (3.56)	0.60 (0.22-1.65)	0.321	21 (2.54)	21 (2.69)	0.93 (0.51-1.71)	0.823	0.461

Hazard ratio (95% CI) from Cox's time-to-first event analyses in ITT population. Continuity corrected risk ratios (95% CI) in case of zero events with Fisher's exact test p-value. Interaction p-value testing for modifying effect of Complex PCI (yes or no) on the hazard ratio scale.
¶includes undetermined Strokes.
NACE = Co-primary composite endpoint of all-cause death, myocardial infarction, stroke and bleeding BARC 3 or 5
MACCE = Co-primary composite endpoint of all-cause death, myocardial infarction, stroke
MCB = Co-primary composite endpoint of bleeding BARC 2, 3 or 5
ACS = STEMI, NSTEMI and Unstable angina.

Figure 1: antiplatelet regimens

A: antiplatelet regimens in complex PCI patients



B: antiplatelet regimens in noncomplex PCI patients



Figure 2: Clinical endpoints stratified by complexity of percutaneous coronary intervention

	Abbreviated DAPT	Standard DAPT	Hazard ratio (95% CI)	Hazard ratio p-value	interaction p-value
Net Adverse Clinical Events					0.595
Complex PCI	49 (8.35)	49 (8.08)	1.03 (0.69-1.52)	0.899	
Noncomplex PCI	123 (7.24)	133 (7.98)	0.90 (0.71-1.15)	0.418	
Major Adverse Cardiac and Cerebral events					0.256
Complex PCI	43 (7.33)	36 (5.94)	1.24 (0.79-1.92)	0.349	
Noncomplex PCI	95 (5.59)	102 (6.12)	0.91 (0.69-1.21)	0.520	
Major or Clinically Relevant Nonmajor Bleeding					0.723
Complex PCI	35 (6.03)	55 (9.15)	0.64 (0.42-0.98)	0.038	
Noncomplex PCI	113 (6.71)	156 (9.44)	0.70 (0.55-0.89)	0.004	
Death					0.553
Complex PCI	19 (3.24)	18 (2.97)	1.09 (0.57-2.07)	0.797	
Noncomplex PCI	56 (3.30)	63 (3.78)	0.87 (0.61-1.25)	0.449	
Cardiovascular death					0.790
Complex PCI	9 (1.55)	10 (1.66)	0.93 (0.38-2.28)	0.869	
Noncomplex PCI	28 (1.66)	34 (2.06)	0.81 (0.49-1.33)	0.398	
Cardiovascular or Undetermined death					0.329
Complex PCI	13 (2.23)	11 (1.83)	1.22 (0.55-2.72)	0.630	
Noncomplex PCI	33 (1.95)	42 (2.53)	0.77 (0.49-1.21)	0.260	
Cerebrovascular Accident					0.452
Complex PCI	4 (0.70)	5 (0.84)	0.82 (0.22-3.07)	0.773	
Noncomplex PCI	13 (0.78)	27 (1.64)	0.47 (0.24-0.91)	0.025	
Myocardial infarction					0.935
Complex PCI	23 (3.97)	19 (3.17)	1.25 (0.68-2.30)	0.471	
Noncomplex PCI	37 (2.21)	30 (1.83)	1.21 (0.75-1.96)	0.436	
Definite or Probable Stent Thrombosis					0.090
Complex PCI	4 (0.69)	6 (1.00)	0.69 (0.19-2.44)	0.562	
Noncomplex PCI	10 (0.60)	3 (0.18)	3.27 (0.90-11.89)	0.071	
BARC Type 2					0.824
Complex PCI	26 (4.49)	42 (7.00)	0.63 (0.38-1.02)	0.060	
Noncomplex PCI	76 (4.52)	110 (6.67)	0.67 (0.50-0.90)	0.007	
BARC Type 3 or 5					0.435
Complex PCI	11 (1.90)	18 (3.00)	0.63 (0.30-1.32)	0.220	
Noncomplex PCI	44 (2.62)	49 (2.97)	0.88 (0.58-1.32)	0.529	



Figure 3



Figure 4: Clinical endpoints in acute coronary syndrome patients stratified by complexity of percutaneous coronary intervention

	Abbreviated DAPT	Standard DAPT	Hazard ratio (95% CI)	Hazard ratio p-value	interaction p-value
Net Adverse Clinical Events					0.683
Complex PCI	28 (9.89)	28 (9.77)	1.00 (0.59-1.69)	0.998	
Noncomplex PCI	68 (8.08)	72 (9.11)	0.88 (0.63-1.23)	0.450	
Major Adverse Cardiac and Cerebral events					0.508
Complex PCI	25 (8.83)	23 (8.02)	1.09 (0.62-1.93)	0.757	
Noncomplex PCI	57 (6.77)	61 (7.72)	0.87 (0.61-1.25)	0.457	
Major or Clinically Relevant Nonmajor Bleeding					0.464
Complex PCI	18 (6.46)	30 (10.68)	0.58 (0.33-1.05)	0.071	
Noncomplex PCI	51 (6.14)	62 (7.93)	0.76 (0.52-1.10)	0.146	
Death					0.695
Complex PCI	12 (4.24)	12 (4.18)	1.00 (0.45-2.23)	0.994	
Noncomplex PCI	33 (3.92)	37 (4.68)	0.83 (0.52-1.33)	0.446	
Cardiovascular death					0.888
Complex PCI	6 (2.15)	8 (2.82)	0.75 (0.26-2.17)	0.598	
Noncomplex PCI	15 (1.80)	17 (2.18)	0.83 (0.41-1.65)	0.587	
Cardiovascular or Undetermined death					0.603
Complex PCI	8 (2.85)	8 (2.82)	1.00 (0.38-2.67)	0.996	
Noncomplex PCI	19 (2.27)	24 (3.06)	0.74 (0.41-1.35)	0.327	
Cerebrovascular Accident					0.931
Complex PCI	1 (0.37)	3 (1.08)	0.33 (0.03-3.20)	0.341	
Noncomplex PCI	6 (0.73)	15 (1.94)	0.37 (0.14-0.96)	0.040	
Myocardial infarction					0.667
Complex PCI	15 (5.39)	12 (4.27)	1.26 (0.59-2.69)	0.552	
Noncomplex PCI	24 (2.90)	22 (2.85)	1.02 (0.57-1.82)	0.946	
Definite or Probable Stent Thrombosis					0.089
Complex PCI	3 (1.08)	5 (1.79)	0.60 (0.14-2.51)	0.485	
Noncomplex PCI	8 (0.97)	2 (0.26)	3.75 (0.80-17.67)	0.094	
BARC Type 2					0.594
Complex PCI	13 (4.69)	22 (7.88)	0.58 (0.29-1.15)	0.117	
Noncomplex PCI	33 (3.98)	42 (5.40)	0.73 (0.46-1.15)	0.170	
BARC Type 3 or 5					0.461
Complex PCI	6 (2.15)	10 (3.56)	0.60 (0.22-1.65)	0.321	
Noncomplex PCI	21 (2.54)	21 (2.69)	0.93 (0.51-1.71)	0.823	



No permission is needed for the figures in the main manuscript or supplementary appendix because all are original.

Disclosure

Marco Valgimigli received an institutional grant from Terumo and consulting fees from Astra Zeneca, Terumo, Alvimedica/CID, Abbott Vascular, Daiichi Sankyo, Bayer, CoreFLOW, DORSIA Pharmaceuticals LTD, Vifor, Bristol Myers Squib SA, Biotronik, Boston scientific, Medtronic, Vesalio, Novartis, Chiesi, PhaseBio, ECRI. Pieter C. Smits received institutional grants from Microport, SMT, Daichy Sankyo and Abbott Vascular; consulting fees from Cavis and Abbott Vascular; honoraria from Abiomed, Terumo and Abbott Vascular; participated on advisory board of Terumo, Abbott Vascular and SMI. Bela Merkely received grants from Medtronic and Boston Scientific; Speaker fee from Biotronik, Abbott, Astra Zeneca, Boehringer Ingelheim and Novartis. Thomas Cuisset received consulting fees from Medtronic, Abbott vascular, Terumo and Boston Scientific; honoraria from Medtronic, Abbott vascular, Terumo and Boston Scientific. Fazila Tun Nesa Malik received consulting fees from Terumo. Krzysztof Reczuch received honoraria from Boston Scientific, Terumo and Astra Zeneca. Pascal Vranckx received consulting fees from Daiichi Sankyo, Novartis, CSL Behring and Bayer AG; honoraria from Daiichi Sankyo and Servier; participated on advisory board for Daiichi Sankyo. All other authors declared no conflict of interest.

ROLE OF THE FUNDING SOURCE

The study was sponsored by the European Cardiovascular Research Institute (ECRI), a non-profit organisation, and received grant support from Terumo. The sponsor and funder had no role in the study design, data collection, data monitoring, analysis, interpretation, or writing of the report.